Clinical trials
Metastatic Breast Cancer clinical trials
Below are recruiting metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 1,334 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06452394RecruitingPhase 2
Testing doxycycline with chemo for breast cancer
This trial tests whether adding the antibiotic doxycycline to standard chemotherapy before surgery can better target breast cancer stem cells in people with ER-positive, HER2-negative breast cancer. The goal is to improve treatment response.
Sankt Gallen, Canton of St. GallenAges 18 years+ - NCT06595966Recruiting
Blood test study for early detection of breast cancer return
This study looks for tiny bits of cancer DNA in your blood after breast cancer surgery. A blood test called NGS may help doctors find early signs of cancer coming back, and you would give samples and have checkups for 3 years.
Hangzhou, ZhejiangAges 18 years+ - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT06610539Recruiting
Magnetic tracer for sentinel node biopsy in breast cancer
This study tests a magnetic tracer call Magtrace to help find and remove the first lymph node (sentinel node) during breast cancer surgery. The goal is to see if it works well for people having breast-conserving surgery.
Chapel Hill, North CarolinaAges 18 years+ - NCT06636981RecruitingPhase 2
Combination therapy for advanced triple negative breast cancer
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06639178Recruiting
Cream to prevent hand-foot syndrome from capecitabine in breast cancer
This trial tests whether a special cream containing N-acetylcysteine and urea can prevent the painful hand-foot syndrome often caused by the chemotherapy drug capecitabine. If you have breast cancer and are about to start capecitabine, this study may help reduce side effects.
Aviano, PordenoneAges 18 years+ - NCT07406087Recruiting
Navigation support for young adults after cancer
This study tests a navigation program to help cancer survivors ages 21-45 get the follow-up care they need. It may be a good fit if you were diagnosed with certain cancers as a teen or young adult.
Pasadena, CaliforniaAges 21–45 - NCT06728579RecruitingPhase 2
Group therapy for joint pain in breast cancer survivors
This study tests two supportive group programs—one using mindfulness skills, the other providing supportive talk therapy—to help breast cancer survivors manage joint pain caused by hormone-blocking pills. If you have ongoing joint pain and are taking an aromatase inhibitor, you may be able to join a free, video-based group.
San Diego, CaliforniaAges 18 years+ - NCT07007169RecruitingPhase 2
Mediterranean diet study for early breast cancer
This trial tests whether eating a Mediterranean-style diet (rich in vegetables, fruits, whole grains, and healthy fats) can help improve outcomes for women with early breast cancer who are receiving chemotherapy. You will be asked to follow this diet and keep a food diary using an online tool.
EsbjergAges 18 years+ - NCT07037199RecruitingPhase 2
A new drug combo for HR+ advanced breast cancer
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07111832RecruitingPhase 3
Study of SHR-A1811 for triple-negative breast cancer
This study tests a new drug called SHR-A1811 for people with triple-negative breast cancer that has spread or come back. It looks at whether the drug can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07295457Recruiting
Exercise to prevent pain from hormone therapy in breast cancer
This trial tests whether starting a gentle exercise program early can help prevent or reduce joint and muscle pain caused by aromatase inhibitors (a common breast cancer medicine). It is for women with hormone-sensitive breast cancer who are not yet experiencing severe pain from their treatment.
LyonAges 18–75 - NCT01000883Recruiting
Biopsy study linking breast cancer tissue markers to treatment response
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
Chapel Hill, North CarolinaAges 18 years+ - NCT02977468RecruitingPhase 1
Pembrolizumab for early triple-negative breast cancer tumor changes
This Phase 1 study tests pembrolizumab (an immune medicine) to see how it affects the tumor and its surroundings in triple-negative breast cancer. It’s mainly looking at safety and early signs of benefit, especially in a limited, early-stage breast tumor.
Atlanta, GeorgiaAges 21–80 - NCT07587957Recruiting
Exercise and Brain Stimulation for Breast Cancer Survivors
This study tests whether combining exercise with a noninvasive brain-stimulation technique (tiny electrical pulses on the scalp) can help improve thinking and memory problems that some breast cancer survivors experience after treatment. Researchers want to see if this combination is practical and safe to use.
Boca Raton, FloridaAges 18 years+ - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07549685Enrolling by invitation
Music Therapy to Help Breast Cancer Patients During Chemotherapy
This study tests whether music therapy can help women with breast cancer feel better during chemotherapy after surgery. Researchers will see if listening to or participating in music sessions improves quality of life and reduces stress during treatment.
AlessandriaAges 25–75 - NCT03769415Recruiting
Using tumor gene data to improve treatment in metastatic breast cancer
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
Chapel Hill, North CarolinaAges 18–99 - NCT05277935Recruiting
Wearable activity tracking for hormone-positive metastatic breast cancer
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
Rio de JaneiroAges 18 years+ - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT05955105RecruitingPhase 1/Phase 2
ILB-2109 plus toripalimab for advanced solid cancers
This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.
Jinan, ShandongAges 18–80 - NCT06010862RecruitingPhase 1
CAR-T therapy for CEA-positive advanced cancers
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
Nanchang, JiangxiAges 18 years+ - NCT06435351RecruitingEarly Phase 1
Personalized vaccine for high-risk triple-negative breast cancer
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Tampa, FloridaAges 18 years+
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer?
- Yes. Clin2 currently lists 1,334 recruiting metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Locally Advanced or Metastatic Breast Cancer
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Advanced/Metastatic Breast Cancer
- Non-metastatic Breast Cancer
- Advanced or Metastatic Breast Cancer
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.